News for Incyte Corporation (0J9P.L)

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck for the India's largest pharmaceutical company to launch its alopecia drug Leqselvi in the United States.

Stocks including TCS, Tata Steel, GAIL (India), Infosys, BHEL, Sun Pharma, NBCC (India), Bharti Hexacom, Eternal, Aurobindo Pharma and TARC will be in the spotlight on Friday, April 10.

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

Incyte (INCY) will announce its Q1 2025 financial results on April 29, 2025, at 7:00 a.m. ET. The company will hold a conference call and webcast at 8:0

Sun Pharmaceutical Industries Ltd on Thursday said a US court has ruled in its favour and vacated a preliminary injunction effective immediately removing restrictions on it launching LEQSELVI, a drug used to treat autoimmune disorder that causes patchy hair loss. Sun Pharma had been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib).

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase

**media[572458]**

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program up

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires.

Shares of biopharmaceutical company Incyte Corporation (INCY) experienced a notable decline, falling 7.32%. This drop followed the release of the phase three tr

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Incyte Corporation INCY fell sharply in today's...

Shares of Precision BioSciences, Inc. DTIL rose sharply in today's pre-market trading. Precision BioSciences reported clearance of investigational new drug app...

Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program ”“TRuE-PN1 and TRuE-PN2 studies ”“ evaluating the safety

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC

**media[552869]**

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health …

Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode.

Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ETCompany ParticipantsBen Strain - Associate Vice President,...